Inroads to Predict in Vivo Toxicology—An Introduction to the eTOX Project

There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical industry has generated in recent decades is not exploited as efficiently as it could be. Enhanced data availability for compound comparison (“read-across”), or for data mining to build predictive tools, should lead to a more efficient drug development process and contribute to the reduction of animal use (3Rs principle). In order to achieve these goals, a consortium approach, grouping numbers of relevant partners, is required. The eTOX (“electronic toxicity”) consortium represents such a project and is a public-private partnership within the framework of the European Innovative Medicines Initiative (IMI). The project aims at the development of in silico prediction systems for organ and in vivo toxicity. The backbone of the project will be a database consisting of preclinical toxicity data for drug compounds or candidates extracted from previously unpublished, legacy reports from thirteen European and European operation-based pharmaceutical companies. The database will be enhanced by incorporation of publically available, high quality toxicology data. Seven academic institutes and five small-to-medium size enterprises (SMEs) contribute with their expertise in data gathering, database curation, data mining, chemoinformatics and predictive systems development. The outcome of the project will be a predictive system contributing to early potential hazard identification and risk assessment during the drug development process. The concept and strategy of the eTOX project is described here, together with current achievements and future deliverables.

[1]  W. Russell,et al.  Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.

[2]  U. Kodavanti,et al.  Cationic amphiphilic drugs and phospholipid storage disorder. , 1990, Pharmacological reviews.

[3]  W H Halliwell,et al.  Cationic Amphiphilic Drug-Induced Phospholipidosis , 1997, Toxicologic pathology.

[4]  U. Busch,et al.  A review of drug‐induced lysosomal disorders of the liver in man and laboratory animals , 1997, Microscopy research and technique.

[5]  G. Gores,et al.  Mechanisms of hepatotoxicity. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  Philip N. Judson,et al.  Using Argumentation for Absolute Reasoning about the Potential Toxicity of Chemicals , 2003, J. Chem. Inf. Comput. Sci..

[7]  Philip N. Judson,et al.  Using Absolute and Relative Reasoning in the Prediction of the Potential Metabolism of Xenobiotics , 2003, J. Chem. Inf. Comput. Sci..

[8]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[9]  B J Blaauboer,et al.  An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing. , 2005, Regulatory toxicology and pharmacology : RTP.

[10]  Tudor I. Oprea,et al.  Descriptor collision and confusion: Toward the design of descriptors to mask chemical structures , 2005, J. Comput. Aided Mol. Des..

[11]  Alfonso Valencia,et al.  Text-mining approaches in molecular biology and biomedicine. , 2005, Drug discovery today.

[12]  David B. Searls,et al.  Data integration: challenges for drug discovery , 2005, Nature Reviews Drug Discovery.

[13]  Y-K Lee,et al.  Validation of an in vitro screen for phospholipidosis using a high-content biology platform , 2006, Cell Biology and Toxicology.

[14]  Iya Khalil,et al.  Achieving confidence in mechanism for drug discovery and development. , 2007, Drug discovery today.

[15]  J. Kramer,et al.  The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates , 2007, Nature Reviews Drug Discovery.

[16]  R Daniel Benz,et al.  Toxicological and clinical computational analysis and the US FDA/CDER , 2007, Expert opinion on drug metabolism & toxicology.

[17]  U. Boelsterli,et al.  Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity? , 2007, Toxicology and applied pharmacology.

[18]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[19]  Naomi L Kruhlak,et al.  Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models , 2008, Toxicology mechanisms and methods.

[20]  Jules C Hancox,et al.  The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.

[21]  Balázs Sarkadi,et al.  The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). , 2008, Drug discovery today.

[22]  Carol A Marchant,et al.  In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.

[23]  H. Federsel,et al.  Handing over the baton: connecting medicinal chemistry with process R&D. , 2008, Drug news & perspectives.

[24]  Chihae Yang,et al.  Toxicity Data Informatics: Supporting a New Paradigm for Toxicity Prediction , 2008, Toxicology mechanisms and methods.

[25]  C. Funk The role of hepatic transporters in drug elimination. , 2008, Expert opinion on drug metabolism & toxicology.

[26]  Alexander Tropsha,et al.  Quantitative structure-activity relationship modeling of rat acute toxicity by oral exposure. , 2009, Chemical research in toxicology.

[27]  Philip Judson,et al.  Using In Silico Tools in a Weight of Evidence Approach to Aid Toxicological Assessment , 2010, Molecular informatics.

[28]  Mark T. D. Cronin,et al.  Recent Advances in QSAR Studies , 2010 .

[29]  Paola Gramatica,et al.  Oral LD50 toxicity modeling and prediction of per- and polyfluorinated chemicals on rat and mouse , 2011, Molecular Diversity.

[30]  M. Bush,et al.  Probabilistic Risk Analysis: Improving Early Drug Development Decision Making , 2010, Clinical pharmacology and therapeutics.

[31]  Jordi Mestres,et al.  Anticipating drug side effects by comparative pharmacology , 2010, Expert opinion on drug metabolism & toxicology.

[32]  A. Bader,et al.  Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages , 2010, Expert opinion on drug metabolism & toxicology.

[33]  Nigel Greene,et al.  The computational prediction of genotoxicity , 2010, Expert opinion on drug metabolism & toxicology.

[34]  Pantelis Sopasakis,et al.  Collaborative development of predictive toxicology applications , 2010, J. Cheminformatics.

[35]  M. Trauner,et al.  Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. , 2010, Pharmacology & therapeutics.

[36]  Ovanes Mekenyan,et al.  Use of genotoxicity information in the development of integrated testing strategies (ITS) for skin sensitization. , 2010, Chemical research in toxicology.

[37]  Nigel Greene,et al.  Developing structure-activity relationships for the prediction of hepatotoxicity. , 2010, Chemical research in toxicology.

[38]  Ferran Sanz,et al.  A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity , 2011, J. Chem. Inf. Model..

[39]  Ivan Rusyn,et al.  Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. , 2011, Chemical research in toxicology.

[40]  MedDRA , 2012, Pharmaceutical Medicine.